Estradiol Valerate (EV, E2V) is an ester prodrug of estradiol and is used in place of estradiol in some medications.
Abbreviation
EV, E2V
References
Names
References
CASRN
979-32-8
References
PubChem CID
13791
ECHA InfoCard
UNII
OKG364O896
KEGG Entry Number
D01413
Wikipedia Entry Name
Estradiol Valerate
ChEBI ID
CHEBI:31561
ChEMBL ID
CHEMBL1511
ChemSpider ID
13194
NIST
Estradiol Valerate
Molecular Formula
C23H32O3
References
Molecular Weight
356.50 g/mol
References
Melting Point
143°–150°
References
Specific Optical Rotation
+41° to +47°, 25 mg (uncorrected for moisture) per mL in dioxane
References
GHS Hazard Code(s)
Class | Category | Code | Description |
---|---|---|---|
Reproductive Toxicity | 1B | H360 | May damage fertility or the unborn child |
Carcinogenicity | 2 | H351 | Suspected of causing cancer if inhaled |
Reproductive Toxicity | 1A | H360FD | May damage fertility. May damage the unborn child |
Reproductive Toxicity, Effects On or Via Lactation | H362 | May cause harm to breast-fed children | |
Acute Oral Toxicity | 4 | H302 | Harmful if swallowed |
Acute Dermal Toxicity | 4 | H312 | Harmful in contact with skin |
Acute Inhalation Toxicity | 4 | H332 | Harmful if inhaled |
Toxicology
See estradiol.
References
MRTD
0.5 mg/kg/day
Pharmacology
See estradiol
References
Estrogen Receptor Activity
Agonist
Bioavailability
IV and intramuscular administration: 100%
Oral: 3%
References
Metabolism
Metabolized by CYP3A4, CYP2C9, UGT
Enzyme Interactions
Inhibits CYP2C19, CYP3A4, CYP2B6
Induces UGTs
Indications
Primary ovarian insufficiency, menorrhagia, hypogonadism, infertility
Discontinued
086865
Discontinued
085860